ad 20

AD 20 is designed to reduce toxicity. It also enhances the activity of anticancer drugs.

PDE5-IN-10 (compound 4b), a potent phosphodiesterase type 5 (PDE5) inhibitor, exhibits an effective half-maximal inhibitory concentration (IC50) of 20 nM, enhanced in vitro microsomal stability (t 1/2 = 44.6 min), and excellent efficacy in restoring long-term potentiation, making it suitable for Alzheimer’s disease (AD) research [1].

AChE BACE1 GSK3β-IN-1 is an orally active, blood-brain barrier-permeable, moderately bioavailable triple inhibitor of AChE, BACE1, and GSK3β, utilized for Alzheimer's disease (AD) research.

BChE-IN-8 (compound 20) is an orally active butyrylcholinesterase (BChE) inhibitor that crosses the blood-brain barrier, targeting eqBChE (IC50: 0.15 nM) and hBChE (IC50: 45.2 nM). It is used in Alzheimer's disease (AD) research for its neuroprotective and cognitive improvement effects, affecting the cholinergic system, Aβ aggregation, and neuropeptide levels.

Q134R, a neuroprotective derivative of hydroxyquinoline, effectively inhibits nuclear factor of activated T-cell (NFAT) signaling and possesses the ability to cross the blood-brain barrier. This compound shows promise for research into Alzheimer’s disease (AD) and aging-related disorders[1].